Search - tctmd.com

Displaying 181 - 198 of 198

Sort: Relevancy | Date

News Conference News AHA 2012

Evidence Continues to Support Dabigatran Treatment in A-fib

November 06, 2012

News Daily News

El Apixaban tiene el Mismo Riesgo Hemorrágico que la Aspirina en Pacientes con FA

L.A. McKeown

October 10, 2012

News Daily News

Apixaban Matches Bleeding Risk of Aspirin in A-fib Patients

L.A. McKeown

October 10, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

L.A. McKeown

August 09, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

News Daily News

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

L.A. McKeown

March 12, 2012

News Daily News

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

L.A. McKeown

March 12, 2012

News Daily News

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

L.A. McKeown

January 09, 2012

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

News Conference News

ESC Congress 2011: Drugs, Devices Work Together

Caitlin E. Cox

September 06, 2011

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

News Daily News

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

Jason Kahn

February 13, 2011

News Daily News

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Jason Kahn

February 09, 2011

CME

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

CME

Advertisement

Evidence Continues to Support Dabigatran Treatment in A-fib

El Apixaban tiene el Mismo Riesgo Hemorrágico que la Aspirina en Pacientes con FA

Apixaban Matches Bleeding Risk of Aspirin in A-fib Patients

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

ESC Congress 2011: Drugs, Devices Work Together

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

Everyday Antiplatelet Decisions: Making the Right Choices

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content